Simcon kunststofftechnische Software (Germany)

Modern transportation network modeling increasingly involves the integration of diverse methodologies including sensor-based forecasting, reinforcement learning, classical flow optimization, and demand modeling that have traditionally been developed in isolation. This paper introduces Flow Through Tensors (FTT), a unified computational graph architecture that connects origin destination flows, path probabilities, and link travel times as interconnected tensors. Our framework makes three key contributions: first, it establishes a consistent mathematical structure that enables gradient-based optimization across previously separate modeling elements; second, it supports multidimensional analysis of traffic patterns over time, space, and user groups with precise quantification of system efficiency; third, it implements tensor decomposition techniques that maintain computational tractability for large scale applications. These innovations collectively enable real time control strategies, efficient coordination between multiple transportation modes and operators, and rigorous enforcement of physical network constraints. The FTT framework bridges the gap between theoretical transportation models and practical deployment needs, providing a foundation for next generation integrated mobility systems.

WorldFAIR and a Festival of Data, looks back on 2022 and forward to 2023. It provides a report on CODATA activities and achievements and highlights the most important upcoming events. 2022 has been another busy and successful year for the CODATA community. We are very grateful for your committed collaboration and engagement with our mission. As a global, membership organisation, CODATA depends on the generosity of our funders and collaborators and the often voluntary efforts of committee, Task Group and Working Group members. In 2023, the International Data Week theme will be ‘a festival of data’ and an occasion to celebrate the richness and diversity of our community. That starts with this expression of gratitude. We are very fortunate to have an extremely committed group of Officers and Executive Committee members, dynamic leadership throughout our various initiatives and a secretariat that works beyond the call of duty. Through all these factors, and more, CODATA is genuinely greater than the sum of its parts and achieves a great deal more than our budget would suggest. As is customary, we would like to provide a summary of activities and achievements and take the opportunity to alert you to events in the coming year. This is a genuinely exciting time, as we see the vision for a Decadal Programme on Making Data Work for Cross-Domain Grand Challenges begin to come into fruition with the WorldFAIR project, a set of related Case Studies, and important work on units, vocabularies and a Cross-Domain Interoperability Framework. Also notable is new impetus and direction for our International Data Policy Committee and the new International Programme Office to support the Open Science initiatives. The report published here ended up a bit longer than intended! I hope it provides an informative and interesting snapshot of CODATA activities. An updated version and a revised CODATA Strategy will be published in 2023 in preparation for our General Assembly, Salzburg, Austria, 27-28 October.

Research by The University of Sheffield for InSinkErator

Hepatitis C Virus (HCV) infection can be associated with a variety of extrahepatic manifestations including metabolic alterations. Few single center studies reported substantial weight gain during and after interferon-free treatment of chronic hepatitis C which has been considered as a potential concern. The aim of this study was to investigate short- and long-term weight changes of patients followed in a large, real-world multicenter cohort.

In 2015, the United States Federal Advisory Committee on Heritable Disorders in Newborns and Children issued recommendations for state-based newborn screening programs to benchmark improvements in newborn-screening timeliness. Newborn screening (NBS) timeliness encompasses the efficient collection, transportation, testing, and reporting of results. Nearly all state programs fail to achieve recommended timeliness benchmarks. Our study explored the processes and procedures that accelerate or hamper progress toward improving NBS timeliness from a public health laboratory program perspective. We conducted semistructured interviews to elicit public health laboratory perspectives on NBS specimen delivery, laboratory testing and processing, communication of results to birthing providers, program staffing, and quality measures and data sharing. A content analysis explored practices, processes, and procedures related to NBS timeliness. A secondary analysis examined interorganizational strategies to enhance timeliness outcomes among NBS stakeholders. Ten laboratories participated in the study (n = 21 personnel). Participants included public health laboratory directors, NBS program managers, and NBS follow-up program staff. Efforts to improve NBS timeliness included engaging birthing providers, expanding courier services, extending operating hours, modifying staffing schedules, and implementing cross-training schedules to facilitate prompt collection, transport, and processing of NBS specimens. Sustained improvements will require implementing robust data systems, integrating laboratory and follow-up processes, and improving communication among all NBS stakeholders. Programs expressed a desire to refine timeliness metric definitions to ensure useful comparisons across states. Efforts to improve timeliness have accelerated in recent years; sustained progress will require increased coordination and integration among stakeholders in the NBS delivery system.

Die interferon-freie DAA-Kombinationstherapie der chronischen Hepatitis C ist hocheffektiv mit virologischen Heilungsraten (SVR) von durchschnittlich über 90%. Dennoch kommt es bei einigen Patienten zu einem virologischen Therapieversagen mit Bildung von resistenten Viren gegenüber den eingesetzten DAA-Klassen, die eine erneute Behandlung erschweren und für die bisher keine zugelassene Therapie zur Verfügung stand. Praktische Erfahrungen mit der seit Kurzem verfügbaren Dreifach-DAA Therapie für DAA-Versager bestehend aus Sofosbuvir/Velpatasvir/Voxilaprevir/(SOF/VEL/VOX) liegen bislang noch nicht vor.

Es ist bekannt, dass eine IFN-freie Behandlung der fortgeschrittenen HCV-assoziierten Leberzirrhose Leberfunktionsparameter u. Pfortaderhochdruck verbessern kann. Erkenntnisse zur langfristigen klinischen Effektivität von DAA-Therapien liegen jedoch nur begrenzt vor. Darüber hinaus wurden Faktoren, die mit einem Fortschreiten der Krankheit assoziiert sind, bislang unzulänglich definiert.

Während die Wirksamkeit der ab 2014 verfügbaren direkt-antiviralen HCV Medikamente (DAA) im Alltag bestätigt wurde, gibt es kaum Daten, die den Einfluss einer DAA-basierten Heilung (SVR12) auf das Wohlbefinden und die klinische Symptomatik in einer breiten Patientenpopulation außerhalb klinischer Studien zeigen.

HCV Genotyp-1-Patienten ohne Zirrhose mit einer Baseline (BL)-Viruslast < 6 Millionen IU/mL können eine auf 8 Wochen verkürzte Therapiedauer mit Ledipasvir/Sofosbuvir (LDV/SOF) erhalten.